Back to search

Article

A recombinant SARS-CoV-2 RBD antigen expressed in insect cells elicits immunogenicity and confirms safety in animal models

2021-11-30

Abstract excerpt

COVID-19 pandemic has accelerated the development of vaccines against its etiologic agent, SARS-CoV-2. However, the emergence of new variants of the virus requires new immunization strategies in addition to the current vaccines approved for human administration. In the present report, the immunological and safety evaluation in mice and hamsters of a subunit vaccine based on the RBD sub-domain with two adjuvants of...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
d6345c07-4bea-5457-b15e-95395810d0dd
DOI
10.1101/2021.11.26.470043
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A recombinant SARS-CoV-2 RBD antigen expressed in insect cells elicits immunogenicity and confirms safety in animal modelsDOI 10.1101/2021.11.26.470043
Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in miceSemantic proximity
Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2Semantic proximity
Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2Semantic proximity
Immunogenicity and in vivo protective effects of recombinant nucleocapsid-based SARS-CoV-2 vaccine Convacell®Semantic proximity
A modular protein subunit vaccine candidate produced in yeast confers protection against SARS-CoV-2 in non-human primatesSemantic proximity
Yeast-expressed Recombinant SARS-CoV-2 Receptor Binding Domain, RBD203-N1 as a COVID-19 Protein Vaccine CandidateSemantic proximity
Safety, Immunogenicity and Efficacy of Relcovax®, A Dual Receptor Binding Domain (RBD) and Nucleocapsid (NC) Subunit Protein Vaccine Candidate Against SARS-CoV-2 VirusSemantic proximity
SARS-CoV-2 RBD219-N1C1: A Yeast-Expressed SARS-CoV-2 Recombinant Receptor-Binding Domain Candidate Vaccine Stimulates Virus Neutralizing Antibodies and T-cell Immunity in MiceSemantic proximity
Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concernSemantic proximity
Recombinant Fc-fusion vaccine of RBD induced protection against SARS-CoV-2 in non-human primate and miceSemantic proximity
Recombinant vaccine containing an RBD-Fc fusion induced protection against SARS-CoV-2 in nonhuman primates and miceSemantic proximity
VSA-2, a novel plant-derived adjuvant for SARS-CoV-2 subunit vaccineSemantic proximity
Select a neighboring publication to make it the new centre.